Last reviewed 2026-04-23 · How we verify

electromotive mitomycin

Electromotive mitomycin works by releasing mitomycin, an alkylating agent, directly into the tumor site.

Electromotive mitomycin works by releasing mitomycin, an alkylating agent, directly into the tumor site. Used for Locally advanced or metastatic solid tumors.

At a glance

Mechanism of action

This localized delivery allows for higher concentrations of mitomycin to be achieved at the tumor site, while minimizing systemic exposure and potential side effects. The electromotive force drives the release of mitomycin, which then intercalates DNA strands, inhibiting DNA replication and ultimately leading to cell death.

Approved indications

• Locally advanced or metastatic solid tumors

Common side effects

• Myelosuppression
• Gastrointestinal toxicity
• Skin reactions

Key clinical trials

• Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure (PHASE2)
• Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer (PHASE3)
• Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection (NA)
• Intravesical Adjuvant Electromotive Mitomycin-C (PHASE2, PHASE3)
• Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer (PHASE3)
• Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.